ChiCTR2300072211 版本V1.0 版本创建时间2023/06/07 09:07:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072211 

最近更新日期:

Date of Last Refreshed on:

2023-06-07 09:07:24 

注册时间:

Date of Registration:

2023-06-07 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

果胶“半固化疗法”对于改善肠内营养耐受性的临床对照性研究

Public title:

A clinical controlled study of pectin "semi-solidification" for improving tolerance to enteral nutrition

注册题目简写:

English Acronym:

研究课题的正式科学名称:

果胶“半固化疗法”对于改善肠内营养耐受性的临床对照性研究

Scientific title:

A clinical controlled study of pectin "semi-solidification" for improving tolerance to enteral nutrition

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李洁 

研究负责人:

朱建华 

Applicant:

li jie 

Study leader:

zhu jianhua 

申请注册联系人电话:

Applicant telephone:

+86 188 5805 1639

研究负责人电话:

Study leader's
telephone:

+86 135 6749 6562

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lijie.200405@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhujianhua201107@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国浙江省宁波市海曙区柳汀街59号

研究负责人通讯地址:

中国浙江省宁波市海曙区柳汀街59号

Applicant address:

59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province, China

Study leader's address:

59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁波市第一医院

Applicant's institution:

Ningbo First Hospital

研究负责人所在单位:

宁波市第一医院

Affiliation of the Leader:

Ningbo First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-R105

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Ningbo First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-07 00:00:00

伦理委员会联系人:

陈少莹

Contact Name of the ethic committee:

chen shaoying

伦理委员会联系地址:

中国浙江省宁波市海曙区柳汀街59号

Contact Address of the ethic committee:

59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 574 8708 5233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁波市第一医院

Primary sponsor:

Ningbo First Hospital

研究实施负责(组长)单位地址:

中国浙江省宁波市海曙区柳汀街59号

Primary sponsor's address:

59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波坤行健医药科技有限公司

具体地址:

中国浙江省宁波高新区宁波新材料创新中心东区1幢1号

Institution
hospital:

Ningbo Kunxingjian Medical Technology Limited company

Address:

No. 1, Building 1, East District, Ningbo New Material Innovation Center, High-tech Zone, Ningbo City, Zhejiang Province,China

经费或物资来源:

宁波坤行健医药科技有限公司

Source(s) of funding:

Ningbo Kunxingjian Medical Technology Limited company

研究疾病:

重症患者  

Target disease:

critical ill patients

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价唯固-低酯果胶能否改善肠内营养耐受性  

Objectives of Study:

Evaluating whether Weigu Low Ester Pectin Can Improve Intestinal Nutrition Tolerance

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)营养风险评分 NRS-2002≥3分的危重无法口服营养的患者; 2)年龄 18-85岁; 3)符合肠内营养启动的标准。

Inclusion criteria

1) Critically ill patients with a nutritional risk score of NRS-2002 ≥ 3 who are unable to receive oral nutrition; 2) Age 18-85 years old; 3) Meets the criteria for enteral nutrition initiation

排除标准:

1)治疗无效最终死亡患者; 2)损伤或有陈旧性胃肠道疾病,无法耐受肠内营养的患者; 3)患有严重肾衰竭、心肌梗死等其他系统重症疾病的患者

Exclusion criteria:

1) Patients with ineffective treatment and ultimate death; 2) Patients with injury or old gastrointestinal diseases who cannot tolerate enteral nutrition; 3) Patients with severe renal failure, myocardial infarction, and other severe systemic diseases

研究实施时间:

Study execute time:

From 2021-12-07 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-19 00:00:00 To 2022-05-31 00:00:00

干预措施:

Interventions:

组别:

果胶组

样本量:

25

Group:

Pectin group

Sample size:

干预措施:

予机械通气、脑保护策略、保护胃肠黏膜、肠内营养支持等,给予肠内营养时添加果胶

干预措施代码:

Intervention:

Mechanical ventilation, brain protection strategy, protection of gastrointestinal mucosa, enteral nutrition support, etc,adding pectin when providing enteral nutrition

Intervention code:

组别:

对照组

样本量:

25

Group:

Control group

Sample size:

干预措施:

予机械通气、脑保护策略、保护胃肠黏膜、肠内营养支持等

干预措施代码:

Intervention:

Mechanical ventilation, brain protection strategy, protection of gastrointestinal mucosa, enteral nutrition support, etc

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市第一医院 

单位级别:

三甲 

Institution
hospital:

Ningbo First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠内营养耐受性

指标类型:

主要指标

Outcome:

Tolerance to enteral nutrition

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠内营养热卡达标率

指标类型:

次要指标

Outcome:

enteral nutrition calorie compliance rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白蛋白

指标类型:

次要指标

Outcome:

Albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前白蛋白

指标类型:

次要指标

Outcome:

prealbumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原

指标类型:

次要指标

Outcome:

procalcitonin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素-6

指标类型:

次要指标

Outcome:

interleukin-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

格拉斯哥昏迷评分

指标类型:

次要指标

Outcome:

glasgow coma score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性生理与慢性健康状况II评分

指标类型:

次要指标

Outcome:

acute physiology and chronic health evaluation Ⅱ score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

序贯器官衰竭评分

指标类型:

次要指标

Outcome:

sequential organ failure score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU住院时间

指标类型:

次要指标

Outcome:

ICU stay time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

28天死亡率

指标类型:

次要指标

Outcome:

28-day mortality rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体质指数

指标类型:

次要指标

Outcome:

Body mass index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据存储管理为自制表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data storage management for homemade tables

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-07 09:07:24